Ponente
Descripción
Radionuclides are widely applied in different medical techniques for treatment and diagnosis. The success of the treatments and imaging, as well as dose minimisation to healthy tissue depend, among other things, on the decay characteristics of the radionuclide in use. This includes the different particles and radiation emitted, the emission energies and the emission probabilities. These are essential for the calculation of the dose administered to the patient in medical imaging or treatment with radioisotopes.
A recent work by Nichols [1], shows a list of radionuclides of actual or potential use in medicine and with deficiencies in their decay data provided. In some of the listed decays the author has explicitly specified the need for a Total Absorption Spectroscopy (TAS) measurement. Among them, 152Tb, and 76Br are used in PET/SPECT and are recommended for a TAS measurement. In particular, 152Tb is a PET isotope that works as theranostic pair of 149Tb, 161Tb and 177Lu used for therapy with labeled PSMA-617 (prostate cancer) or DOTATOC (neuroendocrine cancer).
In this contribution we will present the TAS measurement of 76Br and 152Tb, carried out recently at CERN-ISOLDE and whose decay properties were not well established before.
[1] A.L. Nichols, Radiochim. Acta 110, 609 (2022)
